Diamyd completes screening for US Phase III study
Diamyd Medical has completed the screening of patients for the US Phase
III study, DiaPrevent, ending the recruitment campaign. More than 310
recently diagnosed type 1 diabetes patients between 10 and 20 years of
age have already been enrolled in the study and have received their
first injection of the antigen-based therapy Diamyd® or placebo.
"We expect to reach the enrollment target of 320 patients in the near
future with the patients already enrolled and the ones waiting for their
screening results," says Elisabeth Lindner, CEO and President of Diamyd
Medical. "The study has been met with strong interest by the American
diabetes community and I want to thank everyone who has contributed to
the recruitment effort."
At the same time, the parallel European Phase III study is progressing
according to plan, with the first results anticipated by the spring of
2011. All patients have received their 4 injections of Diamyd® or
placebo, and more than 70 percent have completed their 15 month visit.
When all patients have completed their 15 month visit, the data will be
processed and analyzed.
The global Phase III program aims to investigate whether Diamyd® can
halt or slow the destruction of beta cells in the pancreas in type 1
diabetes, preserving the body's own ability to control the blood sugar
level. This in turn reduces the risk of both short and long term
diabetes complications. In Phase II studies, the Diamyd® therapy has
been shown to slow the loss of beta cell function compared to placebo.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)
Phone: +46 8 661 0026
For pictures and press material, please contact:
Andreas Ericsson, Diamyd Medical AB (publ.)
andreas.ericsson@diamyd.com
Phone: +46 8 661 0026
